Novo Nordisk Launches First GLP-1 Weight-Loss Pill in the U.S.
TL;DR Summary
Novo Nordisk launches the first oral GLP-1 pill for weight loss in the U.S., offering a more affordable and accessible alternative to injections, with prices ranging from $149 to $299 per month, and aims to capture a significant share of the growing obesity treatment market.
- First GLP-1 pill for obesity from Novo Nordisk launches in the U.S. CNBC
- What to watch for in weight loss drugs in 2026: Price changes, GLP-1 pills and more NBC News
- Starter dose of Wegovy now available as a daily pill instead of weekly injection CNN
- The expanding landscape of GLP-1 medicines Nature
- Novo launches Wegovy weight-loss pill for sale in US Reuters
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
3 min
vs 4 min read
Condensed
93%
653 → 45 words
Want the full story? Read the original article
Read on CNBC